Clinical development of PEGylated recombinant staphylokinase (PEG–Sak) for bolus thrombolytic treatment of patients with acute myocardial infarction

The development of bolus thrombolytic agents, in conjunction with bolus anti-thrombotics (e.g. low molecular weight heparins), remains an ambitious but achievable goal of therapy for acute myocardial infarction—a disease which takes the lives of millions each year. This chapter summarizes the data a...

Ausführliche Beschreibung